← Deal Flow

Disruptive

Deep
0Rounds
7Articles
Generating profile summary — check back in a moment.

Highlights

Total Raised
Latest Round
Stage
deep-tech
Employees
Headquarters
News Coverage
7 articles
Last: Today
Talent Signals
SEC Filings

News Coverage 7

DeepToday

Groq raises $650M to become inference cloud after Nvidia deal

Groq pivots from chip maker to cloud services after licensing its LPU to Nvidia for $20B, raising $650M from existing backers to build inference infrastructure.

Deep8d ago

Atomic rethinks version control for AI agents writing code at machine speed

Atomic Software raised $2.5M to build version control designed for AI coding agents, replacing Git's human-centric model with patch theory and provenance tracking.

Defense9d ago

Draganfly, F4 Defense win Army Research Lab counter-drone contract

Draganfly and F4 Defense International selected by DEVCOM Army Research Lab to develop integrated counter-UAS platform combining tethered surveillance, AI tracking, and coordinated defeat capabilities.

Defense19d ago

Firestorm Labs wins $100M Air Force contract for 3D-printed drones

Firestorm Labs lands $100M USAF contract for Tempest 50 sUAS, gaining Air Force backing for expeditionary additive manufacturing that could compress drone production timelines and costs by 80 percent.

Freedom1mo ago

Core Lightning v26.04 RC2: Splicing Graduates to Production

Core Lightning v26.04 RC2 promotes splicing from experimental to stable user-facing commands, enabling channel resizing without downtime. This moves Lightning toward true 'one-balance' wallets and cuts transaction costs in half.

Freedom2mo ago

Core Lightning v26.04rc1 Debuts splicein and spliceout Commands

Core Lightning v26.04rc1, tagged March 26 2026, introduces high-level splicein and spliceout commands that abstract years of low-level splicing complexity into operator-ready RPC calls, marking a structural maturation of Lightning channel management.

Deep2mo ago

FDA Approves Rocket Pharma's KRESLADI: First Gene Therapy for LAD-I

Rocket Pharmaceuticals secured FDA accelerated approval on March 26, 2026 for KRESLADI, the first gene therapy for severe LAD-I, reversing a 2024 manufacturing rejection and unlocking a Rare Pediatric Disease Priority Review Voucher worth $80M–$155M.

Similar Companies 6